Allena Pharmaceuticals, Inc. (ALNA)
| Market Cap | 56.30M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -48.56M |
| Shares Out | 82.57M |
| EPS (ttm) | -0.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 531,300 |
| Open | 0.690 |
| Previous Close | 0.684 |
| Day's Range | 0.670 - 0.700 |
| 52-Week Range | 0.600 - 2.780 |
| Beta | 2.08 |
| Analysts | Strong Buy |
| Price Target | 6.13 (+799.1%) |
| Earnings Date | Nov 8, 2021 |
About ALNA
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients wit...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ALNA stock is "Strong Buy." The 12-month stock price forecast is 6.13, which is an increase of 799.09% from the latest price.
News
Allena Pharmaceuticals, Inc. (ALNA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Allena Pharmaceuticals, Inc. (ALNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisio...
After Plunging 19.7% in 4 Weeks, Here's Why the Trend Might Reverse for Allena Pharmaceuticals, Inc. (ALNA)
The heavy selling pressure might have exhausted for Allena Pharmaceuticals, Inc. (ALNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall...
Allena Pharmaceuticals (ALNA) Sees Hammer Chart Pattern: Time to Buy?
Allena Pharmaceuticals (ALNA) has been struggling lately, but the selling pressure may be coming to an end soon.
Allena Pharmaceuticals to Participate in the Stifel 2021 Virtual Healthcare Conference
NEWTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and c...
Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporate Progress
NEWTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a late-stage biopharmaceutical company deploying its novel oral biologic platfor...
Hot Penny Stocks to Watch as AMC and GME Go to the Moon
Which penny stocks are you watching as GME stock and AMC stock shoot toward the moon? The post Hot Penny Stocks to Watch as AMC and GME Go to the Moon appeared first on Penny Stocks to Buy, Picks, News ...
Allena Pharmaceuticals Receives Fast Track Designation from FDA for the Development of ALLN-346 for Chronic Treatment...
- Novel oral therapeutic candidate ALLN-346 targets uric acid in the intestinal tract -
Allena Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Corporate Progress
NEWTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a late-stage biopharmaceutical company deploying its novel oral biologic platfor...
Allena Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference
NEWTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...
Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-clas...
Allena Pharma Stock Under Pressure After Equity Raise Of $28M
Allena Pharmaceuticals Inc (NASDAQ: ALNA) has announced a registered direct offering of 21.3 million shares and warrants to purchase up to 10.7 million shares at $1.311. With gross proceeds of $28 milli...
Allena Pharmaceuticals Announces $28 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
NEWTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...
Allena Pharmaceuticals, Inc. to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference
NEWTON, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-cla...
Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on ALLN-346 for the Treatment of Gout in Patients w...
Webinar Scheduled for Wednesday, June 16th @ 12 pm EDT Webinar Scheduled for Wednesday, June 16th @ 12 pm EDT
Top Penny Stocks For Your May Watchlist? Check These 5 Out
Looking for penny stocks to buy in May 2021? Here's some watchlist inspiration The post Top Penny Stocks For Your May Watchlist?
Moving Average Crossover Alert: Allena Pharmaceuticals (ALNA)
Allena Pharmaceuticals (ALNA) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Allena Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
-- Enrollment ongoing in Phase 3 URIROX-2 clinical trial of reloxaliase; interim analysis expected 2Q or 3Q 2022 -- -- Enrolling healthy volunteers in Phase 1b MAD study of ALLN-346; initial data expect...
Allena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of Directors
NEWTON, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...
Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
-- Reloxaliase continues to progress through ongoing pivotal Phase 3 URIROX-2 trial for enteric hyperoxaluria -- -- ALLN-346 poised to enter Phase 1 multiple-ascending dose and Phase 2a trials for hyper...
Allena Pharmaceuticals to Present at Upcoming Investor Conferences in March
NEWTON, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzy...
Allena Pharmaceuticals Appoints Richard D. Katz, M.D.
-- Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) -- -- Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) --
Has Allena Pharmaceuticals (ALNA) Outpaced Other Medical Stocks This Year?
Is (ALNA) Outperforming Other Medical Stocks This Year?
Allena Pharmaceuticals, Inc. (ALNA) Moves to Buy: Rationale Behind the Upgrade
Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Allena Pharmaceuticals to Present at Upcoming Investor Conferences in January
NEWTON, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...